VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Compagnie Financiere Richemont SA vs Sanofi
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Compagnie Financiere Richemont SA
CFR · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Compagnie Financiere Richemont SA's moat claims, evidence, and risks.
View CFR analysisSanofi
SAN · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Compagnie Financiere Richemont SA leads (84 / 100 vs 74 / 100 for Sanofi).
- Segment focus: Compagnie Financiere Richemont SA has 3 segments (71.6% in Jewellery Maisons); Sanofi has 3 segments (79.8% in Pharma (Prescription Medicines)).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Compagnie Financiere Richemont SA has 4 moat types across 2 domains; Sanofi has 5 across 3.
Primary market context
Compagnie Financiere Richemont SA
Jewellery Maisons
Luxury jewellery (branded fine jewellery & high jewellery)
Global
Affluent and high-net-worth consumers
Brand owner, manufacturer and direct-to-client retailer
71.6%
Sanofi
Pharma (Prescription Medicines)
Branded prescription pharmaceuticals (immunology, rare disease, neurology, oncology, general medicines)
Global
Patients via payers/providers and channel partners (wholesalers, pharmacies, hospitals)
Research-based drug developer, manufacturer, and marketer
79.8%
Side-by-side metrics
Moat coverage
Shared moat types
Compagnie Financiere Richemont SA strengths
Sanofi strengths
Segment mix
Compagnie Financiere Richemont SA segments
Full profile >Jewellery Maisons
Oligopoly
Specialist Watchmakers
Oligopoly
Other (Fashion & Accessories, Watchfinder, ancillary)
Competitive
Sanofi segments
Full profile >Pharma (Prescription Medicines)
Oligopoly
Vaccines
Oligopoly
Opella (Consumer Healthcare - Sanofi minority stake)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.